[
  {
    "ts": null,
    "headline": "Here's Why Novo Nordisk Stock Popped Today",
    "summary": "Good news from a GLP-1 receptor agonist clinical trial hit the market today.",
    "url": "https://finnhub.io/api/news?id=0e2b12bd139d542c75dee527f96dfd8a0d14d173a42ede7ecb98aaaa2ae4f596",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764095861,
      "headline": "Here's Why Novo Nordisk Stock Popped Today",
      "id": 137605781,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Good news from a GLP-1 receptor agonist clinical trial hit the market today.",
      "url": "https://finnhub.io/api/news?id=0e2b12bd139d542c75dee527f96dfd8a0d14d173a42ede7ecb98aaaa2ae4f596"
    }
  },
  {
    "ts": null,
    "headline": "Rigel Pharmaceuticals: Behind The Huge Rally",
    "summary": "Rigel Pharmaceuticals, Inc. posted a solid Q3 with robust sales growth. Discover insights on future profitability and market outlook. Click for this RIGL update.",
    "url": "https://finnhub.io/api/news?id=10fbd8308888c851886c7082538a7288263114dce4c7cb41a05476e07a17c038",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764093660,
      "headline": "Rigel Pharmaceuticals: Behind The Huge Rally",
      "id": 137607240,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1295160689/image_1295160689.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Rigel Pharmaceuticals, Inc. posted a solid Q3 with robust sales growth. Discover insights on future profitability and market outlook. Click for this RIGL update.",
      "url": "https://finnhub.io/api/news?id=10fbd8308888c851886c7082538a7288263114dce4c7cb41a05476e07a17c038"
    }
  },
  {
    "ts": null,
    "headline": "Novo's Comeback Shot? Weight-Loss Drug Triggers Surprise Rally After Brutal Stock Crash",
    "summary": "A promising next-gen diabetes treatment just gave Novo Nordisk its first real jolt of hope in months.",
    "url": "https://finnhub.io/api/news?id=1ec5cab16dd847471c0de510fd905da76bdc43e7c06b216c974d7118b57ccaef",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764093487,
      "headline": "Novo's Comeback Shot? Weight-Loss Drug Triggers Surprise Rally After Brutal Stock Crash",
      "id": 137605782,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "A promising next-gen diabetes treatment just gave Novo Nordisk its first real jolt of hope in months.",
      "url": "https://finnhub.io/api/news?id=1ec5cab16dd847471c0de510fd905da76bdc43e7c06b216c974d7118b57ccaef"
    }
  },
  {
    "ts": null,
    "headline": "Top analyst drops jaw-dropping price target on Eli Lilly stock",
    "summary": "Bernstein just threw fresh fuel on Eli Lilly's (LLY) never-ending rally, as the firm lifted its price target on the stock to $1,300 from $1,100. For perspective, that’s an 18% bump compared to the old target, while representing a 21% to 22% upside compared to Lilly’s current stock price. ...",
    "url": "https://finnhub.io/api/news?id=da8967cdebc44d4eba388b37def20950b2eee8f03f4f1fd2e1b4dd234f4193c4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764091980,
      "headline": "Top analyst drops jaw-dropping price target on Eli Lilly stock",
      "id": 137605783,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Bernstein just threw fresh fuel on Eli Lilly's (LLY) never-ending rally, as the firm lifted its price target on the stock to $1,300 from $1,100. For perspective, that’s an 18% bump compared to the old target, while representing a 21% to 22% upside compared to Lilly’s current stock price. ...",
      "url": "https://finnhub.io/api/news?id=da8967cdebc44d4eba388b37def20950b2eee8f03f4f1fd2e1b4dd234f4193c4"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Stock Jumps on Positive Weight-Loss Drug Data. Why It Deserves Better.",
    "summary": "Shares, though, were punished Monday after the drug maker said its blockbuster obesity treatment Wegovy failed to slow Alzheimer’s.",
    "url": "https://finnhub.io/api/news?id=b0283a3dc8885651cfbff03768f4cf3481f167d55b85a0fa96030016cb3178f1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764082260,
      "headline": "Novo Nordisk Stock Jumps on Positive Weight-Loss Drug Data. Why It Deserves Better.",
      "id": 137605784,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Shares, though, were punished Monday after the drug maker said its blockbuster obesity treatment Wegovy failed to slow Alzheimer’s.",
      "url": "https://finnhub.io/api/news?id=b0283a3dc8885651cfbff03768f4cf3481f167d55b85a0fa96030016cb3178f1"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Drug Helps Patients Lose Weight, Lower Blood Sugar in Trial",
    "summary": "The pharma giant said amycretin helped patients lose weight and reduce blood-sugar levels in pill and injection forms during a mid-stage trial, lifting shares in the company.",
    "url": "https://finnhub.io/api/news?id=3f8dda141eaeb677c0d049cc4fc37fbbe61b52bfb7065187b61304824f7b6576",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764082020,
      "headline": "Novo Nordisk Drug Helps Patients Lose Weight, Lower Blood Sugar in Trial",
      "id": 137605785,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The pharma giant said amycretin helped patients lose weight and reduce blood-sugar levels in pill and injection forms during a mid-stage trial, lifting shares in the company.",
      "url": "https://finnhub.io/api/news?id=3f8dda141eaeb677c0d049cc4fc37fbbe61b52bfb7065187b61304824f7b6576"
    }
  },
  {
    "ts": null,
    "headline": "Redditors Are Buying Eli Lilly And Co (LLY) Ahead of Potential End of AI Trade. Here’s Why",
    "summary": "We recently published Top 10 Non-AI Stocks Redditors are Buying Ahead of Potential Bubble Burst. Eli Lilly And Co (NYSE:LLY) is one of the top non-AI stocks redditors are buying. Eli Lilly And Co (NYSE:LLY) recently posted strong quarterly results amid robust growth from its diabetes and weight-loss products. With a diverse portfolio spanning oncology, […]",
    "url": "https://finnhub.io/api/news?id=249ebb2f810f30f8bd45869e554ca254e93a5db292cb929b3508a0db406a2cce",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764078037,
      "headline": "Redditors Are Buying Eli Lilly And Co (LLY) Ahead of Potential End of AI Trade. Here’s Why",
      "id": 137605786,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published Top 10 Non-AI Stocks Redditors are Buying Ahead of Potential Bubble Burst. Eli Lilly And Co (NYSE:LLY) is one of the top non-AI stocks redditors are buying. Eli Lilly And Co (NYSE:LLY) recently posted strong quarterly results amid robust growth from its diabetes and weight-loss products. With a diverse portfolio spanning oncology, […]",
      "url": "https://finnhub.io/api/news?id=249ebb2f810f30f8bd45869e554ca254e93a5db292cb929b3508a0db406a2cce"
    }
  },
  {
    "ts": null,
    "headline": "A Trillion-Dollar Pill: Eli Lilly Broke the Healthcare Ceiling",
    "summary": "Eli Lilly became the first drugmaker to surpass a trillion-dollar valuation by driving revenue through mass market adoption rather than price increases.",
    "url": "https://finnhub.io/api/news?id=f5ebc6479a226a03407fd6ed817f771ac3cc4ccf20297dcff28044c0a88994d5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764077940,
      "headline": "A Trillion-Dollar Pill: Eli Lilly Broke the Healthcare Ceiling",
      "id": 137612586,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly became the first drugmaker to surpass a trillion-dollar valuation by driving revenue through mass market adoption rather than price increases.",
      "url": "https://finnhub.io/api/news?id=f5ebc6479a226a03407fd6ed817f771ac3cc4ccf20297dcff28044c0a88994d5"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: Forget About Alzheimer's, The Real Catalyst Is The Wegovy Pill",
    "summary": "Novo Nordisk A/S is rated a Strong Buy with a huge unmet demand in obesity treatment and a low 13x P/E ratio. Learn more about NVO stock here.",
    "url": "https://finnhub.io/api/news?id=b8743f3aa444808cb2dd9dee9ac74ca94973036da90d9a19385cd3090fcfb301",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764076689,
      "headline": "Novo Nordisk: Forget About Alzheimer's, The Real Catalyst Is The Wegovy Pill",
      "id": 137605394,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/175212421/image_175212421.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk A/S is rated a Strong Buy with a huge unmet demand in obesity treatment and a low 13x P/E ratio. Learn more about NVO stock here.",
      "url": "https://finnhub.io/api/news?id=b8743f3aa444808cb2dd9dee9ac74ca94973036da90d9a19385cd3090fcfb301"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare ETF (IYH) Hits New 52-Week High",
    "summary": "IYH hits a 52-week high as healthcare gains momentum, lifted by sector strength and rising investor interest in safety and AI-driven tailwinds.",
    "url": "https://finnhub.io/api/news?id=9946197063791f40cad51eb88fd38311414849a029d08b3247c35002a52f0dc7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764074820,
      "headline": "Healthcare ETF (IYH) Hits New 52-Week High",
      "id": 137605787,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "IYH hits a 52-week high as healthcare gains momentum, lifted by sector strength and rising investor interest in safety and AI-driven tailwinds.",
      "url": "https://finnhub.io/api/news?id=9946197063791f40cad51eb88fd38311414849a029d08b3247c35002a52f0dc7"
    }
  },
  {
    "ts": null,
    "headline": "J&J Up Around 17% in 3 Months: Should You Buy, Sell or Hold the Stock?",
    "summary": "J&J's 16.7% rise reflects stronger sales guidance, rapid pipeline advances and improving MedTech momentum amid a recovering sector.",
    "url": "https://finnhub.io/api/news?id=42ccd668993012cedf9961a5de78b1ccac4b109d2a8e69f66ad59467c5c6ace0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764073440,
      "headline": "J&J Up Around 17% in 3 Months: Should You Buy, Sell or Hold the Stock?",
      "id": 137605788,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "J&J's 16.7% rise reflects stronger sales guidance, rapid pipeline advances and improving MedTech momentum amid a recovering sector.",
      "url": "https://finnhub.io/api/news?id=42ccd668993012cedf9961a5de78b1ccac4b109d2a8e69f66ad59467c5c6ace0"
    }
  },
  {
    "ts": null,
    "headline": "Citizens Financial Group And 2 Other Stocks That May Be Priced Below Their Estimated Worth",
    "summary": "As the U.S. stock market kicks off a holiday-shortened trading week with significant gains, investors are buoyed by optimism around a potential Federal Reserve interest rate cut in December. In this environment of heightened confidence, identifying stocks that may be undervalued compared to their estimated worth can be particularly appealing, as they offer opportunities for growth amidst broader market enthusiasm.",
    "url": "https://finnhub.io/api/news?id=d56f2d6e17b16b3633d0b901d5b344759e1378d835fafb314f01867ec73a9caa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764070680,
      "headline": "Citizens Financial Group And 2 Other Stocks That May Be Priced Below Their Estimated Worth",
      "id": 137602752,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "As the U.S. stock market kicks off a holiday-shortened trading week with significant gains, investors are buoyed by optimism around a potential Federal Reserve interest rate cut in December. In this environment of heightened confidence, identifying stocks that may be undervalued compared to their estimated worth can be particularly appealing, as they offer opportunities for growth amidst broader market enthusiasm.",
      "url": "https://finnhub.io/api/news?id=d56f2d6e17b16b3633d0b901d5b344759e1378d835fafb314f01867ec73a9caa"
    }
  },
  {
    "ts": null,
    "headline": "How Is Eli Lilly’s Stock Performance Compared to Other Pharmaceuticals?",
    "summary": "Eli Lilly’s remarkable outperformance within the pharmaceutical sector hasn’t tempered enthusiasm, analysts are still strongly bullish on its long-term growth potential.",
    "url": "https://finnhub.io/api/news?id=1ce5b58b1dca199650404b993c7f5fc09df2c09891de12e606e59bb8ef2c944f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764067949,
      "headline": "How Is Eli Lilly’s Stock Performance Compared to Other Pharmaceuticals?",
      "id": 137605789,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly’s remarkable outperformance within the pharmaceutical sector hasn’t tempered enthusiasm, analysts are still strongly bullish on its long-term growth potential.",
      "url": "https://finnhub.io/api/news?id=1ce5b58b1dca199650404b993c7f5fc09df2c09891de12e606e59bb8ef2c944f"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights LLY, EPHE, BBC, HELX, XHS and SURI",
    "summary": "LLY, EPHE, BBC, HELX, XHS and SURI headline last week's top-performing ETFs as healthcare and biotech outperform a weak broader market.",
    "url": "https://finnhub.io/api/news?id=f9873fa52c6e96faad476dc934b2a63bbf431aecba27b222d99c3ccc51162008",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764060240,
      "headline": "The Zacks Analyst Blog Highlights LLY, EPHE, BBC, HELX, XHS and SURI",
      "id": 137602753,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "LLY, EPHE, BBC, HELX, XHS and SURI headline last week's top-performing ETFs as healthcare and biotech outperform a weak broader market.",
      "url": "https://finnhub.io/api/news?id=f9873fa52c6e96faad476dc934b2a63bbf431aecba27b222d99c3ccc51162008"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk's Longshot Alzheimer's Trial Didn't Work, But It Is Still Worth Buying",
    "summary": "Novo Nordisk A/S remains a Strong Buy despite semaglutide's Alzheimer's trial miss. Click for NVO growth drivers, solid fundamentals, and attractive dividend yield.",
    "url": "https://finnhub.io/api/news?id=05145ad236af590705887e122f08d0114b2a465ed3c669a309f7de02364eaa26",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764059878,
      "headline": "Novo Nordisk's Longshot Alzheimer's Trial Didn't Work, But It Is Still Worth Buying",
      "id": 137603491,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2169883679/image_2169883679.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk A/S remains a Strong Buy despite semaglutide's Alzheimer's trial miss. Click for NVO growth drivers, solid fundamentals, and attractive dividend yield.",
      "url": "https://finnhub.io/api/news?id=05145ad236af590705887e122f08d0114b2a465ed3c669a309f7de02364eaa26"
    }
  },
  {
    "ts": null,
    "headline": "4 takeaways from pharma’s manufacturing boom",
    "summary": "As pharma’s U.S. facility investments top $370 billion over the next five years, there are a few things to keep in mind, according to construction experts.",
    "url": "https://finnhub.io/api/news?id=233c1cf0383ff95697693c76296957c552c00161be33434d5f001e66289d5726",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764057600,
      "headline": "4 takeaways from pharma’s manufacturing boom",
      "id": 137605790,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "As pharma’s U.S. facility investments top $370 billion over the next five years, there are a few things to keep in mind, according to construction experts.",
      "url": "https://finnhub.io/api/news?id=233c1cf0383ff95697693c76296957c552c00161be33434d5f001e66289d5726"
    }
  },
  {
    "ts": null,
    "headline": "Morgan Stanley Maintains Eli Lilly and (LLY) Overweight Recommendation",
    "summary": "Morgan Stanley Maintains Eli Lilly and (LLY) Overweight Recommendation",
    "url": "https://finnhub.io/api/news?id=8d387f15696b76ee829d4671e6b5aeeb0f429cdc73c677b127119c209a343877",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764029048,
      "headline": "Morgan Stanley Maintains Eli Lilly and (LLY) Overweight Recommendation",
      "id": 137599005,
      "image": "",
      "related": "LLY",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=8d387f15696b76ee829d4671e6b5aeeb0f429cdc73c677b127119c209a343877"
    }
  },
  {
    "ts": null,
    "headline": "Bernstein Maintains Eli Lilly and (LLY) Outperform Recommendation",
    "summary": "Bernstein Maintains Eli Lilly and (LLY) Outperform Recommendation",
    "url": "https://finnhub.io/api/news?id=451fadd2c2dec4bbef569bee841c9abd2f35c03fc5d68348509eb769b04138db",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764028988,
      "headline": "Bernstein Maintains Eli Lilly and (LLY) Outperform Recommendation",
      "id": 137599022,
      "image": "",
      "related": "LLY",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=451fadd2c2dec4bbef569bee841c9abd2f35c03fc5d68348509eb769b04138db"
    }
  }
]